File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Elevated levels of transforming growth factor-β1 in serum of patients with stable bronchiectasis
  • Basic View
  • Metadata View
  • XML View
TitleElevated levels of transforming growth factor-β1 in serum of patients with stable bronchiectasis
 
AuthorsMak, JCW1
Ho, SP1
Leung, RYH1
Ho, PL1
Ooi, C1
Tipoe, GL1
Yan, C1
Ip, MSM1
Lam, WK1
Tsang, KWT1
 
KeywordsBronchiectasis
Serum
Transforming growth factor-β1
 
Issue Date2005
 
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/rmed
 
CitationRespiratory Medicine, 2005, v. 99 n. 10, p. 1223-1228 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.rmed.2005.02.039
 
AbstractBronchiectasis is a chronic inflammatory and infective airway disease characterized by irreversible dilatation of the bronchi and persistent purulent sputum. Transforming growth factor-β1 (TGF-β1) has been found to be increased in the lungs or bronchoalveolar lavage fluid of patients with inflammatory lung diseases. However, little is known on the serum TGF-β1 levels in patients with bronchiectasis. We aimed to determine the serum TGF-β1 concentrations in 95 patients with stable bronchiectasis (63 women; mean±SD age, 58.9±14.1 years) and 68 control subjects (23 women; 48.9±12.8 years) by ELISA, and to correlate with clinical parameters. The serum TGF-β1 levels were significantly higher in bronchiectatic patients compared with control subjects (median [range], 1812.5 pg/ml [1226.4-4114.5 pg/ml] vs. 1342.4 pg/ml [940.3-2371.7 pg/ml]; P < 0.001). There was, however, no correlation between serum TGF-β1 levels with FEV1 (% predicted), FVC (% predicted), 24 h sputum volume, the number of bronchiectatic lung lobes or total white blood cell count (P>0.05). Our findings support previous indications that TGF-β1 may contribute to bronchiectatic airway inflammation. Further studies on the potential mechanisms and pathogenesis implications of this elevation should also be pursued in future. © 2005 Elsevier Ltd. All rights reserved.
 
ISSN0954-6111
2013 Impact Factor: 2.917
 
DOIhttp://dx.doi.org/10.1016/j.rmed.2005.02.039
 
ISI Accession Number IDWOS:000232182500004
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorMak, JCW
 
dc.contributor.authorHo, SP
 
dc.contributor.authorLeung, RYH
 
dc.contributor.authorHo, PL
 
dc.contributor.authorOoi, C
 
dc.contributor.authorTipoe, GL
 
dc.contributor.authorYan, C
 
dc.contributor.authorIp, MSM
 
dc.contributor.authorLam, WK
 
dc.contributor.authorTsang, KWT
 
dc.date.accessioned2012-06-26T05:56:23Z
 
dc.date.available2012-06-26T05:56:23Z
 
dc.date.issued2005
 
dc.description.abstractBronchiectasis is a chronic inflammatory and infective airway disease characterized by irreversible dilatation of the bronchi and persistent purulent sputum. Transforming growth factor-β1 (TGF-β1) has been found to be increased in the lungs or bronchoalveolar lavage fluid of patients with inflammatory lung diseases. However, little is known on the serum TGF-β1 levels in patients with bronchiectasis. We aimed to determine the serum TGF-β1 concentrations in 95 patients with stable bronchiectasis (63 women; mean±SD age, 58.9±14.1 years) and 68 control subjects (23 women; 48.9±12.8 years) by ELISA, and to correlate with clinical parameters. The serum TGF-β1 levels were significantly higher in bronchiectatic patients compared with control subjects (median [range], 1812.5 pg/ml [1226.4-4114.5 pg/ml] vs. 1342.4 pg/ml [940.3-2371.7 pg/ml]; P < 0.001). There was, however, no correlation between serum TGF-β1 levels with FEV1 (% predicted), FVC (% predicted), 24 h sputum volume, the number of bronchiectatic lung lobes or total white blood cell count (P>0.05). Our findings support previous indications that TGF-β1 may contribute to bronchiectatic airway inflammation. Further studies on the potential mechanisms and pathogenesis implications of this elevation should also be pursued in future. © 2005 Elsevier Ltd. All rights reserved.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationRespiratory Medicine, 2005, v. 99 n. 10, p. 1223-1228 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.rmed.2005.02.039
 
dc.identifier.doihttp://dx.doi.org/10.1016/j.rmed.2005.02.039
 
dc.identifier.epage1228
 
dc.identifier.hkuros118977
 
dc.identifier.isiWOS:000232182500004
 
dc.identifier.issn0954-6111
2013 Impact Factor: 2.917
 
dc.identifier.issue10
 
dc.identifier.pmid16140222
 
dc.identifier.scopuseid_2-s2.0-24344442810
 
dc.identifier.spage1223
 
dc.identifier.urihttp://hdl.handle.net/10722/149640
 
dc.identifier.volume99
 
dc.languageeng
 
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/rmed
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofRespiratory Medicine
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAdult
 
dc.subject.meshAged
 
dc.subject.meshBronchiectasis - Blood - Etiology
 
dc.subject.meshCase-Control Studies
 
dc.subject.meshChina
 
dc.subject.meshEnzyme-Linked Immunosorbent Assay
 
dc.subject.meshFemale
 
dc.subject.meshHumans
 
dc.subject.meshMale
 
dc.subject.meshMiddle Aged
 
dc.subject.meshTransforming Growth Factor Beta - Metabolism
 
dc.subject.meshTransforming Growth Factor Beta1
 
dc.subjectBronchiectasis
 
dc.subjectSerum
 
dc.subjectTransforming growth factor-β1
 
dc.titleElevated levels of transforming growth factor-β1 in serum of patients with stable bronchiectasis
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Mak, JCW</contributor.author>
<contributor.author>Ho, SP</contributor.author>
<contributor.author>Leung, RYH</contributor.author>
<contributor.author>Ho, PL</contributor.author>
<contributor.author>Ooi, C</contributor.author>
<contributor.author>Tipoe, GL</contributor.author>
<contributor.author>Yan, C</contributor.author>
<contributor.author>Ip, MSM</contributor.author>
<contributor.author>Lam, WK</contributor.author>
<contributor.author>Tsang, KWT</contributor.author>
<date.accessioned>2012-06-26T05:56:23Z</date.accessioned>
<date.available>2012-06-26T05:56:23Z</date.available>
<date.issued>2005</date.issued>
<identifier.citation>Respiratory Medicine, 2005, v. 99 n. 10, p. 1223-1228</identifier.citation>
<identifier.issn>0954-6111</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/149640</identifier.uri>
<description.abstract>Bronchiectasis is a chronic inflammatory and infective airway disease characterized by irreversible dilatation of the bronchi and persistent purulent sputum. Transforming growth factor-&#946;1 (TGF-&#946;1) has been found to be increased in the lungs or bronchoalveolar lavage fluid of patients with inflammatory lung diseases. However, little is known on the serum TGF-&#946;1 levels in patients with bronchiectasis. We aimed to determine the serum TGF-&#946;1 concentrations in 95 patients with stable bronchiectasis (63 women; mean&#177;SD age, 58.9&#177;14.1 years) and 68 control subjects (23 women; 48.9&#177;12.8 years) by ELISA, and to correlate with clinical parameters. The serum TGF-&#946;1 levels were significantly higher in bronchiectatic patients compared with control subjects (median [range], 1812.5 pg/ml [1226.4-4114.5 pg/ml] vs. 1342.4 pg/ml [940.3-2371.7 pg/ml]; P &lt; 0.001). There was, however, no correlation between serum TGF-&#946;1 levels with FEV1 (% predicted), FVC (% predicted), 24 h sputum volume, the number of bronchiectatic lung lobes or total white blood cell count (P&gt;0.05). Our findings support previous indications that TGF-&#946;1 may contribute to bronchiectatic airway inflammation. Further studies on the potential mechanisms and pathogenesis implications of this elevation should also be pursued in future. &#169; 2005 Elsevier Ltd. All rights reserved.</description.abstract>
<language>eng</language>
<publisher>Elsevier Ltd. The Journal&apos;s web site is located at http://www.elsevier.com/locate/rmed</publisher>
<relation.ispartof>Respiratory Medicine</relation.ispartof>
<subject>Bronchiectasis</subject>
<subject>Serum</subject>
<subject>Transforming growth factor-&#946;1</subject>
<subject.mesh>Adult</subject.mesh>
<subject.mesh>Aged</subject.mesh>
<subject.mesh>Bronchiectasis - Blood - Etiology</subject.mesh>
<subject.mesh>Case-Control Studies</subject.mesh>
<subject.mesh>China</subject.mesh>
<subject.mesh>Enzyme-Linked Immunosorbent Assay</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Male</subject.mesh>
<subject.mesh>Middle Aged</subject.mesh>
<subject.mesh>Transforming Growth Factor Beta - Metabolism</subject.mesh>
<subject.mesh>Transforming Growth Factor Beta1</subject.mesh>
<title>Elevated levels of transforming growth factor-&#946;1 in serum of patients with stable bronchiectasis</title>
<type>Article</type>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/j.rmed.2005.02.039</identifier.doi>
<identifier.pmid>16140222</identifier.pmid>
<identifier.scopus>eid_2-s2.0-24344442810</identifier.scopus>
<identifier.hkuros>118977</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-24344442810&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>99</identifier.volume>
<identifier.issue>10</identifier.issue>
<identifier.spage>1223</identifier.spage>
<identifier.epage>1228</identifier.epage>
<identifier.isi>WOS:000232182500004</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong